Autologous serum Therapy of the ocular surface with Novel Delivery by Platelet Concentrate Gel

2006 ◽  
Vol 4 (4) ◽  
pp. 188-195 ◽  
Author(s):  
Bruce H. Koffler
Keyword(s):  
Ocular Surface ◽  
Platelet Concentrate ◽  
Autologous Serum ◽  
Serum Therapy

scholarly journals Use of Acellular Umbilical Cord-Derived Tissues in Corneal and Ocular Surface Diseases

Medicines ◽  
2021 ◽  
Vol 8 (2) ◽  
pp. 12
Author(s):  
Arianna A. Tovar ◽  
Ian A. White ◽  
Alfonso L. Sabater
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Ocular Surface ◽  
Cellular Proliferation ◽  
Mononuclear Cells ◽  
Autologous Serum ◽  
High Concentration ◽  
Ocular Surface Diseases ◽  
Natural Healing

Blood derived products have become a valuable source of tissue for the treatment of ocular surface diseases that are refractory to conventional treatments. These can be obtained from autologous or allogeneic sources (patient’s own blood or from healthy adult donors/umbilical cord blood, respectively). Allogeneic cord blood demonstrates practical advantages over alternatives and these advantages will be discussed herein. Umbilical cord blood (UCB) can be divided, generally speaking, into two distinct products: first, mononuclear cells, which can be used in regenerative ophthalmology, and second, the plasma/serum (an acellular fraction), which may be used in the form of eyedrops administered directly to the damaged ocular surface. The rationale for using umbilical cord serum (UCS) to treat ocular surface diseases such as severe dry eye syndrome (DES), persistent epithelial defects (PED), recurrent epithelial erosions, ocular chemical burns, graft versus host disease (GVHD), among others, is the considerably high concentration of growth factors and cytokines, mimicking the natural healing properties of human tears. Allogeneic serum also offers the opportunity for therapeutic treatment to patients who, due to poor heath, cannot provide autologous serum. The mechanism of action involves the stimulation of endogenous cellular proliferation, differentiation and maturation, which is highly efficient in promoting and enhancing corneal epithelial healing where other therapies have previously failed.

scholarly journals Clinical Outcome of Autologous Serum Therapy in Chronic Idiopathic Urticaria

2017 ◽  
Vol 15 (1) ◽  
pp. 71-74 ◽  
Author(s):  
Dharmendra Karn ◽  
Shekhar KC
Keyword(s):  
Skin Prick Test ◽  
Chronic Urticaria ◽  
Statistical Significance ◽  
Cost Effective ◽  
Chronic Idiopathic Urticaria ◽  
Autologous Serum ◽  
P Value ◽  
Prick Test ◽  
H1 Antihistamines ◽  
Serum Therapy

Background: Quality of life in chronic idiopathic urticaria is hampered as efficacy of H1-antihistamines is limited. Autologous serum containing tolerance-generating anti-idiotype antibodies is a novel and cost-effective therapy. This study was conducted to evaluate the efficacy of autologous serum therapy (AST) among chronic urticaria patients with autologous skin prick test positive and negative status.Methods: Untreated 102 patients of chronic urticaria were enrolled in a non-randomized interventional study. Patients were categorized into two groups based on autologous serum skin prick test as test positive (ASST +) and test negative (ASST -). Patients were then treated with intramuscular injection of 0.05ml per kg body weight of autologous serum weekly for 10 weeks. Urticaria activity scoring (UAS) tool was used for quantification of the symptoms. Weekly recording of UAS (range: 0-42) was made before the therapy (baseline) and during the therapy for 10 weeks.Results: Significant improvement with AST in the mean UAS was noted from baseline to 10 weeks in both the group of patients (14.6 ± 6.3 and 10.2 ± 5.1 for ASST+ group; 16.9 ± 7.8 and 8.6 ± 4.8 for ASST- group; at baseline and 10 weeks, respectively (p-value for both <0.05)). However no statistical significance was found while comparing the efficacy of the therapy against ASST + and ASST - Groups (p-value > 0.05).Conclusions: Irrespective of autologous skin prick test results, autologous serum therapy showed significant improvement in patients with chornic idiopathic urticaria. AST can, thus, be an effective treatment modality for it.

scholarly journals Comparison of treatment efficacy between 100% platelet-rich plasma and 100% serum eye drops in moderate-to-severe dry eye disease: a randomised controlled trial protocol

BMJ Open ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. e048479
Author(s):  
Passara Jongkhajornpong ◽  
Pawin Numthavaj ◽  
Thunyarat Anothaisintawee ◽  
Kaevalin Lekhanont ◽  
Gareth McKay ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Platelet Rich Plasma ◽  
Controlled Trial ◽  
Dry Eye Disease ◽  
Autologous Serum ◽  
Eye Disease ◽  
Eye Drops ◽  
Department Of Ophthalmology ◽  
Autologous Platelet

IntroductionDry eye disease (DED) is a common eye problem. Although the disease is not fatal, it substantially reduces quality of life and creates a high economic burden, especially in patients with moderate-to-severe DED. Several biological tear substitutes (eg, autologous serum (AS), autologous platelet-rich plasma (APRP) and autologous platelet lysate) could effectively improve dry eyes. However, evidence on their comparative efficacy is controversial. This study aims to compare the efficacy of 100% APRP with 100% AS eye drops in patients with moderate-to-severe DED.Methods and analysisThe study is a single-centre, double-blinded randomised, parallel, non-inferiority trial. One hundred and thirty patients with moderate-to-severe DED, aged 18–70 years will be recruited from outpatient clinic, Department of Ophthalmology, Ramathibodi Hospital, Bangkok from February 2021 to January 2023. Patients will be randomised to receive either 100% APRP or 100% AS eye drops (1:1 ratio) for 4 weeks. The primary outcomes are ocular surface disease index (OSDI) and ocular surface staining (OSS) evaluated using the Oxford scale. Secondary outcomes are fluorescein break-up time, Schirmer’s I test, meibomian gland parameters and adverse events. Other measured outcomes include best-corrected visual acuity, intraocular pressure and compliance.Ethics and disseminationThe study protocol and any supplements used in conducting this trial have been approved by the Ethics Committee of Faculty of Medicine, Ramathibodi Hospital, Mahidol University (MURA2020/1930). Informed consent will be obtained from all patients before study entry. Results will be presented in peer-reviewed journals and international conferences.Trial registration numberNCT04683796.

scholarly journals EFFECTIVENESS OF AUTOLOGOUS SERUM THERAPY IN CHRONIC URTICARIA: A PROSPECTIVE OBSERVATIONAL STUDY IN TERTIARY CARE HOSPITAL

2016 ◽  
Vol 5 (17) ◽  
pp. 822-827
Author(s):  
Rakesh Kumar Patel ◽  
Anil Kumar Gupta ◽  
Santosh Kumar Singh ◽  
Harleen Chhachhi ◽  
Pawan Kumar Patel ◽  
...  
Keyword(s):  
Observational Study ◽  
Chronic Urticaria ◽  
Prospective Observational Study ◽  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Autologous Serum ◽  
Care Hospital ◽  
Serum Therapy

scholarly journals Autologous serum therapy in chronic urticaria: Old wine in a new bottle

2008 ◽  
Vol 74 (2) ◽  
pp. 109 ◽  
Author(s):  
AK Bajaj ◽  
Abir Saraswat ◽  
Amitabh Upadhyay ◽  
Rajetha Damisetty ◽  
Sandipan Dhar
Keyword(s):  
Chronic Urticaria ◽  
Autologous Serum ◽  
Serum Therapy

scholarly journals The Role of Multisystem Disease in Composition of Autologous Serum tears and ocular surface symptom improvement

2020 ◽  
Vol 18 (3) ◽  
pp. 499-504
Author(s):  
Madeline Ripa ◽  
Sayena Jabbehdari ◽  
Ghasem Yazdanpanah ◽  
Emoke Lukacs ◽  
Brandon Karcher ◽  
...  
Keyword(s):  
Ocular Surface ◽  
Autologous Serum ◽  
Symptom Improvement ◽  
Multisystem Disease

scholarly journals Effect of Autologous Serum Eyedrops on Ocular Surface Disease Caused by Preserved Glaucoma Eyedrops

2020 ◽  
Vol 9 (12) ◽  
pp. 3904
Author(s):  
Ha-Rim So ◽  
Hae Young Lopilly Park ◽  
So-Hyang Chung ◽  
Hyun-Seung Kim ◽  
Yong-Soo Byun
Keyword(s):  
Ocular Surface ◽  
Ocular Surface Disease ◽  
Autologous Serum ◽  
Ocular Surface Disease Index ◽  
Ocular Surface Diseases ◽  
Group 3 ◽  
Baseline Values ◽  
Group 2 ◽  
Group 1

Autologous serum eyedrops (ASE) are effective in treating various ocular surface diseases, including damages induced by long-term use of preserved glaucoma eyedrops. However, there has been no study on whether ASE is effective without stopping the causative eyedrops. This retrospective observational study included 55 patients with ocular-surface diseases caused by long-term use of preserved glaucoma eyedrops: 18 patients who used ASEs for 2 months without discontinuing the use of glaucoma eyedrops (Group 1), 22 patients who used ASEs for 2 months, discontinuing the use of glaucoma eyedrops for the first month (Group 2) and 15 patients who used non-preservative artificial tears for 2 months, discontinuing the use of glaucoma eyedrops for the first month (Group 3). There were no intergroup differences in the baseline values of the Schirmer I test results, tear breakup time (TBUT), ocular surface staining (OSS) score, loss of the meibomian gland, meibum quality and ocular-surface disease index (OSDI). Group 1 showed significant differences in TBUT, OSS score and OSDI at 2 months when compared to the baseline values before treatment, while Group 2 showed significant differences in those values at both 1 and 2 months. There were no differences in any of the parameters at baseline, 1 month or 2 months in Group 3. Our result suggested that ASE is effective for treating ocular surface diseases caused by glaucoma eyedrops containing preservatives and its effects can be expected without interruption of glaucoma eyedrop treatment.

scholarly journals Evaluation of the Efficacy of 50% Autologous Serum Eye Drops in Different Ocular Surface Pathologies

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Francesco Semeraro ◽  
Eliana Forbice ◽  
Osvaldo Braga ◽  
Alessandro Bova ◽  
Attilio Di Salvatore ◽  
...  
Keyword(s):  
Ocular Surface ◽  
Conventional Therapy ◽  
Keratoconjunctivitis Sicca ◽  
Signs And Symptoms ◽  
Autologous Serum ◽  
Eye Drops ◽  
Blurred Vision ◽  
Group 2 ◽  
Serum Eye Drops ◽  
Group 1

Purpose. This study evaluated the efficacy of 50% autologous serum eye drops in ocular surface diseases not improved by conventional therapy.Methods. We analyzed two groups: (1) acute eye pathologies (e.g., chemical burns) and (2) chronic eye pathologies (e.g., recurrent corneal erosion, neurotropic keratitis, and keratoconjunctivitis sicca). The patients were treated for surface instability after conventional therapy. The patients received therapy 5 times a day until stabilization of the framework; they then reduced therapy to 3 times a day for at least 3 months. We analyzed the best corrected visual acuity, epithelial defects, inflammation, corneal opacity, and corneal neovascularization. We also analyzed symptoms such as tearing, burning, sense of foreign body or sand, photophobia, blurred vision, and difficulty opening the eyelids.Results. We enrolled 15 eyes in group 1 and 11 eyes in group 2. The average therapy period was 16 ± 5.86 weeks in group 1 and 30.54 ± 20.33 weeks in group 2. The epithelial defects all resolved. Signs and symptoms improved in both groups. In group 2, the defect recurred after the suspension of therapy in 2 (18%) patients; in group 1, no defects recurred.Conclusions. Autologous serum eye drops effectively stabilize and improve signs and symptoms in eyes previously treated with conventional therapy.

Sign in / Sign up

Export Citation Format

Share Document